Abstract: Objective Liver injury is common in many chronic liver disease, and liver disease has a systemic impact, and vice versa. Diagnosis and treatment of patients with liver disease should not only consider the liver disease itself, but also need to clarify patho-physiological mechanisms by which the interaction occur between various systemic diseases and inflammatory liver injury. Therefore, the dealing with liver injury often require multidisciplinary discussions and joint decision-making. One of the important aspects of liver disease treatment is to protect and maintain the stability of liver functions, and how to carry out anti-inflammatory and liver protection involves etiology and liver injuries for appropriate treatment strategies. Bicyclol is a chemical agent independently developed in China and has a widespread administration to treat patients with inflammatory liver injury. Bicyclol has a good preventive and therapeutic efficacy on inflammatory liver injury caused by various etiologies documented in literature, and has been registered and listed in nine countries along the Belt and Road. We have organized domestic experts from relevant disciplines all over the country to summarize multidisciplinary clinical application of bicyclol in the prevention and treatment of inflammatory liver injury abide on liver disease diagnosis and treatment guidelines/consensus/clinical pathways and evidence-based medicine, combined with clinical practice in China. The aim of this consensus is to improve the reasonable and standardized clinical application of bicyclol in the treatment of patients with inflammatory liver injury.

Key words: Inflammatory liver injury, Bicyclol, Multidisciplinary, Clinical application, Pharmacological effects, Therapy